BARCELONA, Aug 30 (Reuters) – A new medicine from Novartis
could replace drugs that have been central to treating
heart failure for a quarter of century, after proving remarkably
effective in reducing deaths in a keenly awaited study.
The experimental treatment, known at LCZ696, cut the risk of
both cardiovascular death and admissions to hospital by a fifth,
boosting hopes for a product seen as a multibillion-dollar
seller – thanks, in part, to its expected premium price.
BARCELONA (Reuters) – A Boston Scientific device that stimulates the vagus nerve – a superhighway connecting the brain to the rest of the body – failed to help patients with heart failure in a mid-stage clinical trial.
Vagus nerve stimulation (VNS), which involves delivering mild electrical pulses to the nerve in the neck, is already used to treat epilepsy and depression – and researchers have been looking to expand its use to other conditions.
BARCELONA (Reuters) – A new heart failure drug from Novartis cut the risk of both cardiovascular death and hospitalization by a fifth in a keenly awaited study, boosting hopes for a product that is seen as a multibillion-dollar seller.
There has been little progress for more than a decade in treating chronic heart failure, in which the heart fails to pump enough blood around the body, so there is excitement about the new medicine among both doctors and investors.
Fantasy Premier League 2014/15 – Official App by Premier Leagues https://t.co/flWTr44bau
LONDON (Reuters) – Hopes for AstraZeneca’s promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.
The drug, which is designed to help the immune system fight tumours, will be tested in 48 patients with advanced disease in the Phase II trial, according to an update on the website clinicaltrials.gov.